ENOV
Enovis CORPPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | $104M | first quarter ended April 3, 2026 | — |
|
|
|||
| adjusted EBITDA margin non-GAAP | 17.6% | first quarter ended April 3, 2026 | — |
| adjusted net earnings per diluted share non-GAAP | $0.89 | first quarter ended April 3, 2026 | — |
| adjusted earnings per share non-GAAP | $0.89 | Q1 2026 call | — |
| adjusted gross margins non-GAAP | 62% | Q1 2026 call | — |
| days adjusted organic growth | 6% | Q1 2026 call | — |
| days adjusted organic growth in P&R | 3% | Q1 2026 call | — |
| days adjusted organic growth in Recon | 8% | Q1 2026 call | — |
| extremities organic growth | 10% | Q1 2026 call | — |
| free cash flow year-over-year improvement | $16M | Q1 2026 call | — |
| global bracing days adjusted growth | 3% | Q1 2026 call | — |
| Hips and Knees organic growth | 6% | Q1 2026 call | — |
| international Recon organic growth | 3% | Q1 2026 call | — |
| organic growth in Prevention & Recovery | 1% | Q1 2026 call | — |
| organic growth in Recon | 6% | Q1 2026 call | — |
| organic revenue growth | 3% | Q1 2026 call | — |
| P&R days adjusted growth | 3% | Q1 2026 call | — |
| selling days headwind | 240 | Q1 2026 call | — |
| tariffs paid | $4M | Q1 2026 call | — |
| U.S. Recon organic growth | 8% | Q1 2026 call | — |
| underlying adjusted EPS growth non-GAAP | 10% | Q1 2026 call | — |
| underlying gross margin improvement | 40 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENOV
this stock
Enovis CORP
|
$1.51B | -1.5% | +6.7% | — | 16.5% |
|
ABT
Abbott Laboratories
|
$154.95B | -28.6% | +5.7% | 24.9 | 1.3% |
|
SYK
Stryker Corp
|
$119.25B | -11.3% | +11.2% | 36.0 | 1.8% |
|
MDT
Medtronic plc
|
$101.51B | -16.8% | +8.4% | 21.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$63.36B | -55.3% | +5.5% | 17.8 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENOV | +1.4% | +24.3% | +9.5% | +26.8% | -1.5% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | +1.6% | +22.7% | +1.2% | +26.5% | -11.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.